This inhibition is comparable to the effect of the mechanistic target of rapamycin complex 1 (mTORC1) inhibitor rapamycin, as both TGF-β and rapamycin reduce NK cell proliferation, granzyme B expression and cytotoxicity against tumour cells. Here, TGFB1 is linked to neoplasm.